SMI.London 2025 will continue the dialogue on soft mist inhalers (SMIs) initiated in 2023, offering a comprehensive examination of their evolving role in inhaled drug delivery.
The programme will highlight the advantages of SMIs compared to other inhalation devices and address the scientific and regulatory frameworks shaping their development. Discussions will span the full development cycle—from active molecules to final dosage forms—and feature presentations by leading experts with deep experience in inhalation therapies.
